SCOTTSDALE, Ariz. -- Nuvilex, Inc. (OTCQB: NVLX) announced its President and CEO, Dr. Robert F. Ryan, has conducted an exclusive audio-taped webcast interview with The Green Baron Report, allowing NVLX shareholders and the investment community an opportunity to learn more about the Company's overall and recent developments and plans. Unrestricted access to the webcast is now available on the "Webcasts" page at www.TheGreenBaron.com.
We are extremely pleased to note that The Green Baron Report initiated coverage of Nuvilex, Inc. as its "Stock Pick of the Year" through a report released to its members after the market closed yesterday, Monday, May 23rd, 2011. The extremely bullish forecast is supported by press that Nuvilex is acquiring the rights to a therapeutic treatment for pancreatic cancer that has already completed initial clinical trials. The report adds that, "A price target of $0.50 per share recently set by Goldman Small Cap Research may clearly be in reach, and continued strong new developments could support raising this price target further."
About The Green Baron Report
The Green Baron Report is a subsidiary of Evergreen Marketing. The Green Baron Report is an internet based stock market newsletter that focuses on low priced stocks that appear to have significant upside potential. For more information about Evergreen Marketing, Inc. and their subsidiary The Green Baron Investors Society visit them on the web at http://www.EvergreenMarketingInc.com and http://www.TheGreenBaron.com. Our disclaimer can be viewed at http://www.thegreenbaron.com/Disclaimer.htm. Investors who wish to receive The Green Baron Report for free can join at http://www.thegreenbaron.com/Join.htm.
Nuvilex isO
a Green Company believing in "Good for You, Good for the Environment" and are expanding our natural product lines and will be making important strides in the biotechnology arena (www.nuvilex.com). Current products include Cinnergen[TM] for healthy glucose maintenance; Cinnechol[TM] to maintain healthy lipids and cardiovasculature; Cinnsational[TM] to decrease detrimental alcohol effects; Talsyn[TM] for keloids, erythema, and scar management; NumaDerm[TM] cosmetic products; Citroxin[TM] and Oraphyte[TM] antimicrobial and antinematodal agents; Reme-Flu[TM], Legacy Biotechnologies' flu combating regimen; and Virgin[R] and Infinitink[R], heavy-metal-free tattoo inks.
Safe Harbor Statement
This information may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Nuvilex's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
No comments:
Post a Comment